News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis AG Withdraws Joicela Marketing Application in Europe
April 19, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Novartis AG (NOVN) withdrew its application to market the Joicela pain pill in the European Union because the Swiss company wasn’t able to provide information to regulators in the time allowed.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Novartis
MORE ON THIS TOPIC
Vaccines
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule
January 6, 2026
·
3 min read
·
Dan Samorodnitsky
FDA
FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025
January 6, 2026
·
3 min read
·
Heather McKenzie
Opinion
Addressing the Regulatory Reality of Replacing
In Vivo
Models in Drug Development
January 5, 2026
·
6 min read
·
Xiaoxia Li
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
January 2, 2026
·
2 min read
·
Nick Paul Taylor
